People

Genzyme founder, biotech entrepreneur and industry legend Henri Termeer dies

Henri Termeer, one of the greatest and most successful visionaries in biotech, has died. According to the Boston Globe, Termeer collapsed at his Marblehead home on Friday evening. He was 71.

Termeer’s legacy rests on growing Genzyme into a world leader in orphan drug R&D, developing drugs for tiny patient populations, saving lives and pioneering an aggressive pricing strategy that made the field a popular focus among a whole generation of startups. (The 10 most expensive therapies on the planet are all orphan drugs.) Sanofi CEO Chris Viehbacher saw the value, and bought the company for about $20 billion in 2011, after Termeer had run the company for 30 years — a rare feat in this industry.

Over the last six years, Termeer stayed active in biotech, serving on boards at Moderna, Verastem and others and investing part of the $158 million windfall of cash he earned in the Sanofi buyout in a long lineup of upstarts. Arrakis, founded by serial entrepreneur Michael Gilman, was the most recent to earn his support just last February. He backed Kees Been as a co-founder at Lysosomal Therapeutics. And he clearly enjoyed working with many of his old Genzyme colleagues as they left to take other positions in the Biotech/Cambridge biotech hub he helped create.

He never lost his love of launching new companies.

“It is just in that phase of trying to define its identity and what it is going to develop all the way by itself,” Termeer said of Moderna back in 2013 in an interview with FierceBiotech. “That is a fantastic moment because with that you shape what the future will look like.”

Termeer always kept focused on shaping the future. And biotech will be feeling the effects for years to come.

We’ve gathered a few tributes from Twitter and we’ll continue to add to this through Sunday.

Image: Feb. 16, 2011: Henri Termeer, chief executive officer of Genzyme, listens during a news conference announcing the deal where France’s Sanofi-Aventis agreed to buy Termeer’s company, ending a nine-month pursuit of Genzyme. Bloomberg via Getty Images

 


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Bulletin Healthcare

Immuno Oncology 360